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>50% ($671$130) . Because many larger hospitals purchase contrast
media below list price through various contracts, the reduction in
the hospital's differential cost would likely be even greater .
Numerous other factors must be considered when selecting a
contrast medium for use in an angiographic procedure . For example,
although the analysis of Powe et al . considers the costs incurred, it
fails to estimate the opportunity cost or potential loss of revent e by
the hospital or physician, or both, due to the increased average time
treating adverse reactions in patients given high osmolality contrast
media. Other important perspectives omitted from the authors'
analysis include those of the patient, physician and staff . A recent
study by Hopper and Matthews (4) demonstrated that when low risk
patients were given a choice of contrast media as part of an informed
consent procedure, nearly half of them opted for low over high
osmolality contrast media, even if they were required to pay a cost
differential of $100 to $150. In that study, 63% of the low risk
patients surveyed felt the choice of contrast media should be left to
the individual patient . Another recent study, by Debatin et al . (5),
demonstrated that physicians would be inclined to use low osmolal-
ity contrast media universally if given the choice . That study
showed that when physicians were allowed to decide within certain
guidelines which patients were at high risk for an adverse reaction .
over time they expanded the definition of a high risk patient and
increased their use of low osmclality contrast media .
The report by Powe et . al . is an analysis of data previously
published in the New England Journal of Medicine (6) . Although the
authors carefully documented information regarding costs incurred,
the data used for both analyses are compromised by the extensive
screening of potential study participants . Only 26% of the cardiac
catheterization patients examined at Johns Hopkins during the study
period (50511955) were enrolled in the study because of numerous
preselection criteria, among which were refusal of the patient to give
informed consent, unwillingness on the part of the physician to
enroll patients, a clinical determination that low osmolality contrast
media was warranted, the likelihood of another contrast-enhanced
study within 48 h, patient history of contrast reaction of preexisting
renal insufficiency . Even given these enrollment biases . the inci .
dence of mild and moderate adverse events was mr-e than three
times higher with high than with low osmolality contrast media . In
addition, the average: per-patient cost of treating reactions was much
greater than in the high than in the low osmolality contrast media
group. In a trial with randomized, consecutive patient +rollment, it
is likely that the incidence of adverse events and the per-patient
treatment costs of adverse events in the high osmolality contrast
media group would be even higher in comparison with the low
osmolality contrast media group .
In this study (6), as in previous comparative studies, the single
greatest risk factor, and the only one totally controlled by the
physician, was the choice of contrast medium . The study showed
that even in patients at very low risk, adverse events were three
times more frequent among patients given high osmolality contrast
media. The study also showed that the cost of treating adverse
reactions in can be significantly higher in a high than in a low
osmolality contrast media group. Despite significant protocol biases
in favor of high osmolality contrast media, the analysis of Powe et
al . demonstrated that the differential cost to the hospital of using low
osmolality contrast media may be reduced by >50% when the cost
of treating adverse reactions is considered . Considering the actual
price and volume of contrast media used today, universal use of low
osmolality contrast media for angiocardiographic procedures may
be cost-effective from a societal point of view . These findings lend
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additional support to the argument that factors other than the list
price of low osmclality contrast media need to be considered when
deciding which type of contrast media to use for angiocardiographic
procedures .
Ultimately, regardless of any cost differential, the patients'
welfare should be the primary consideration . As the 1993 ACC
guidelines on the use of contrast media (7) indicate, individual
patients in consultation with their physicians are best suited to make
the decision regarding the use of high or low osmolality contrast
media for an angiographic procedure .
ADEOYE Y. OLUKOTUN, MD, FACC
Squibb Diagnostics
P
.O . Box 45,70
Princeton, Net, Jessev (18540 .4500
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Zbrozek raises two issues concerning ou' • economic analysis of low
versus liigh osmolality contrast media in diagnostic angiocardio
graE hy . The first concerts the most appropriate estimate of the cost
of adverse reactions . Our analysis protocol was designed to com-
pare the cost (from three perspectives) of high versus low osmolality
contrast media-induced adverse reactions of any severity and
contrast material costs. In our baseline analysis, we used the mean
costs that we observed for high and low osmolality contrast media-
induced reactions . After examining the frequency and costs of
adverse reactions by subgroups defined by severity level, it became
evident that the magnitude of the offset of the difference in material
cost related to o, . verse reactions was driven by level 4 (severe)
adverse reactions . We, therefore, examined the sensitivity of our
results to the -ost of level 4 adverse reactions . This post-hoc
analysis showed an estimated 15% offset of the difference in material
cost between high and low osmolality contrast media when pooled
level 4 costs were used . The observed costs within each severity
level were higher among patients receiving high than among patients
receiving low osmolality contrast media . Although, the differences
in the mean cost of adverse reactions of a given severity by type of
contrast media were not statistically significant, our power to detect
a true difference was low . We believe that the approach we took in
our analyses was reasonable . However, our data are presented in
sufficient detail to permit others to make their own assumptions,
calculations and conclusions, as both Zbrozek and Olukotun have
done .
The second issue raised by Zbrozek is that of the impact of
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premedications to avert adverse reactions . We did not assess either
the cost or the effect of prophylactic treatments that might affect the
rate of allergiclike reactions. Adverse reactions that are allergic in
nature are infrequent in cardiac procedures compared with those
reactions thought to arise from myocardial depressant and electro-
physiologic effects of contrast medium . At our hospital, in diagnos-
tic angiocardiography, H2-receptor blockers such as cimetidine are
not routinely administered . Empiric evidence on the costs and
effects of various pretreatment regimens in patients undergoing
diagnostic angiocardiography would be useful .
Olukotun makes several points about our studies and analyses,
some of which have already been addressed (1) . The first relates to
our comparison of universal use of low versus universal use of high
osmolality contrast media . We compared universal or no use of each
type of medium to provide the most conservative estimate of any
saving in the overall cost of contrast medium due to a reduction in
the cost of managing adverse reactions . We agree that the most
cost-effecaive use of low osmolality contrast media would be to limit
their use to patients at greatest risk for adverse reactions . Although
several studies (2,3) have identified associations between specific
patient characteristics and the risk of adverse reactions in patients
undergoing diagnostic angiocardiography, prospectively validated
studies of the impact of application of targeting strategies have not
been reported to our knowledge. Even if reliable targeting strategies
whose application would permit more cost-effective use were avail-
able, some catheterization laboratories may not wish to manage the
logistics of risk stratification .
Another issue raised by Olukotun is the dose of contrast medium
used in our study and its associated cost . We agree that the total
dose of contrast medium used in our cardiac catheterizatinn labo-
ratory is higher than that in many other laboratories . If a smaller
average dose of contrast medium had been injected, adverse reac-
tions and their associated costs also might have been different from
those we observed . Our estimates of the cost of contrast media were
based on the size of the bottle or bottles that were opened during the
procedure rather than an injected contrast medium . Clearly, the cost
of contrast medium would be less if smaller or fewer bottles were
opened . Further savings could be achieved through the development
of innovative, safe and inexpensive ways to package or deliver
contrast medium (e .g ., trultidose systems) that would reduce wast-
age (4) .
With regard to assignment of the material cost of contrast media
and the costs of resources used to manage adverse reactions, we
used those incurred during the time our study was conducted . Both
contrast material costs as well as adverse reaction costs are subject
to change for a variety of reasons, including substitution of more or
less expensive resource inputs and changes in the cost of inputs that
may be influenced by market forces and the time value of money .
The cost of using low osmolality contrast media would be lower if
the price were lower, a circumstance possibly constrained by higher
manufacturing costs, royalties paid to patent owners or the cost of
pharmaceutical research and development (5).
We did take account of time spent managing adverse reactions
induced by high versus low osmolality contrast media . In our
estimates of cost to the hospital (differential cost), administrators
were interviewed to assess whether the difference in staff time spent
managing adverse reactions induced by high versus low osmolality
contrast media would result in savings
. In our analysis of societal
cost (average cost), extra time spent in the procedure room was
assigned the average cost of the additional labor and space to
operate the catheterization laboratory and accounted for a small
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amount, 4%, of the average cost of managing adverse reactions . We
cannot comment on whether revenue was, in fact, lost by the
hospital or by physicians (opportunity cost) as a result of the time
spent managing adverse reactions or whether patients incurred
costs, because we did not measure such costs in this study . In a
prior study (6), we found that 47% of patients were willing to pay
>$100 if low osmolality contrast media reduced the risk of bot l
major (life-threatening arrhythmia, nephrotoxicity, severe allergic
reaction or death) and minor (flushing, nausea, hives and pain)
adverse reactions, but fewer patients were willing to pay $100 if
these agents reduced the risk of only minor adverse reactions .
Finally, as Olukotun suggests, our selection criteria excluded pa-
tients at the highest risk for adverse reactions . Thus, our results
cannot be generalized to patient populations that include very
compromised patients .
The concerns of Zbrozek and Olukotun exemplify the need for
rigorous empiric studies of expensive pharmaceutical agents that
examine both clinical and economic outcomes from multiple per-
spectives . Such studies can provide information that can be useful in
making difficult decisions in a health care environment in which the
cost of patient care must be considered in addition to health
outcomes .
NEIL R. POWE, MD, MPH, MBA
JEFFREY A. BRINKER, MD, FACC
RICHARD D. MOORE, MD, MHS
EARL P. STEINBERG . MD, MPP
The Johns Hopkins Medical Institutions
Balti»tore, Maryland 21287
References
1 . Stcinberg EP . Moore RD, Powe NR . Gopalan R, Brinker JA . High-osmolality and low
osmolality contrast agents. N Engi J Med 1997 :327 :204 .
2 . Barrett BJ, Parfrey PS, Vavasour HM, O'dea F, Kent G, Stone E . A comparison of
nonionic, low .osmolality radiocontrast agents with ionic . high-osmolality agents during
cardiac catheterization . N Engl J Mcd 1992 :326:431-6.
3 . Steinberg EP, Moore RD, Powc NR a al . Safety and cost-effectiveness of high
osmoiality as compared with low osmoiality contrast mateial in patients undergoing
cardiac angiography . N Engl J Mcd 199' ;326 :425-30.
4 . Kinnison ML, Steinberg EP, Powe NR, Anderson GF . Reducing the cost of using
contrast media : a look at discarded volumes . Radiology 1988 ;166:367-70.
5 . U .S . Congress, Office of Technology Assessment . Pharmaceutical R&D: Costs . Risks
and Rewards . OTA-H-522, Washington. DC, U .S . Government Printing Office. Febru-
ary 1993 .
6 . Appel U. Steinberg EP . Fowe . NR, Anderson OF, Dwyer SA, Faden RR . Risk
reduction from low osmolality cumrast media : what do patients think it is worth? Med
Care 1990 :28 :324-37 .
Spontaneous Closure of Atrial Septal Defects
The title and abstract of this oth:rwise well done study by Radzik et
al . (I) are somewhat misleading . In the Discussion section, the
authors acknowledge that many of their subjects had an incompetent
foramen ovale rather than a "defect ." Because >50°% of premature
infants with delayed closure of a ductus arteriosus will have a left to
right shunt through an incompetent foramen ovale (2), it is unnec-
essarily alarming to refer to an incompetent foramen ovate as a
defect, raising the specter of future open heart surgery . In addition,
blurring this distinction confuses the physiology of two distinct
processes.
Radzik and colleagues did not investigate the role of left atrial
enlargement in left to right shunts at the atrial level . The foramen
ovale is widely patent at birth, after 9 months of right to left shunting
